India's patent laws under pressure: The Lancet special report

September 10, 2012

In a special report in The Lancet, researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements.

The report, which is published today (Monday), highlights by two , Bayer and , to key provisions of India's Patents Act. Bayer's appeal was heard last week, and the Indian Supreme Court is due to hear Novartis' appeal tomorrow (11th September).

In their report, "India's patent laws under pressure", Peter Roderick, a barrister, and Allyson Pollock, Professor of Public Health Research and Policy, both from the Centre for Primary Care and Public Health at Queen Mary, University of London, say that the Bayer and Novartis cases "are seeking to undermine public health considerations aimed at improving access and therapeutic advantage".

They conclude: "There are many problems facing access to and rational use of medicines in India but the provisions within the country's patent laws, if more extensively and properly applied, should help rather than hinder such access. India's laws and experiences could provide a useful example for low-income and middle-income countries worldwide."

The report outlines the history and details of the two cases, including an analysis of some of the legal background to the actions.

Explore further: India patent case threatens cheap drug supply: MSF

More information: "India's patent laws under pressure", by Peter Roderick and Allyson Pollock. The Lancet.

Related Stories

India patent case threatens cheap drug supply: MSF

September 5, 2011

Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.

NGOs protest Novartis' Glivec patent quest in India

February 23, 2012

Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

Bayer mulls challenge to India cancer drug ruling

March 13, 2012

Bayer AG said Tuesday it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant.

Bayer challenges India cancer drug ruling

May 6, 2012

German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

Recommended for you

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.